Get the Stockscreener App
5.70
7.32%
-0.45
After Hours:
5.70
Aura Biosciences Inc stock is traded at $5.70, with a volume of 285.94K.
It is down -7.32% in the last 24 hours and up +6.34% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$6.15
Open:
$6.08
24h Volume:
285.94K
Relative Volume:
1.45
Market Cap:
$361.97M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-2.9688
EPS:
-1.92
Net Cash Flow:
$-64.56M
1W Performance:
-4.68%
1M Performance:
+6.34%
6M Performance:
-12.04%
1Y Performance:
-23.90%
1-Day Range:
$5.695
$6.23
1-Week Range:
$5.46
$6.33
52-Week Range:
$4.345
$7.73
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
5.70 | 390.55M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Resumed | Evercore ISI | Outperform |
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
View All
Aura Biosciences Inc Stock (AURA) Latest News
Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference - Yahoo Finance
AURA: Late-stage oncology programs show strong safety, efficacy, and market potential, with key data ahead - TradingView
Aura's Bel-sar — One Asset, Multiple Oncology Opportunities - RTTNews
Aura Biosciences (AURA) officer granted RSUs and 112,661-share option - Stock Titan
Aura Biosciences (AURA) officer receives RSU and option grants - Stock Titan
Large equity awards to Elisabet de los Pinos at Aura Biosciences (AURA) - Stock Titan
Aura Biosciences (AURA) CTO receives new stock option and RSU awards - Stock Titan
Aura Biosciences (AURA) grants stock options and RSUs to its CMO - Stock Titan
Aura Biosciences (AURA) SVP awarded 80,472 options and 44,528 RSUs - Stock Titan
Aura Biosciences Posts Q2 Cash Surge - AOL.com
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wall Street Recap: Is Aura Biosciences Inc in a long term uptrend2025 Technical Overview & Risk Managed Investment Strategies - baoquankhu1.vn
Aura Biosciences, Inc. (AURA) Stock Analysis: A Biotech Gem With 235% Potential Upside - DirectorsTalk Interviews
AURA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aura Biosciences plans fireside chats at three March healthcare events - Stock Titan
Update Recap: Is Aura Biosciences Inc stock undervalued right now2025 Pullback Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Understanding Momentum Shifts in (AURA) - Stock Traders Daily
Aura Biosciences, Inc. (AURA) Stock Analysis: Assessing a Potential 300% Upside in Biotech Innovation - DirectorsTalk Interviews
Aura Biosciences Expands Evidence With New Patient-Reported Outcome Study in Eye Cancer - TipRanks
Ocular melanoma Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Delcath System, Aura Biosciences, Seagen, IDEAYA, Ascentage Pharma - Barchart.com
Aura Biosciences (NASDAQ:AURA) SVP Amy Elazzouzi Sells 8,549 Shares - MarketBeat
What makes Aura Biosciences (AURA) a new buy stock - MSN
Are Medical Stocks Lagging Assertio (ASRT) This Year? - Bitget
Can Aura Biosciences Inc. outperform under higher oil prices2025 Investor Takeaways & Growth Focused Entry Point Reports - mfd.ru
Is Aura Biosciences Inc. exposed to currency risksBreakout Watch & Growth Oriented Trade Recommendations - mfd.ru
What Makes Aura Biosciences (AURA) a New Buy Stock - Yahoo Finance
Aura Biosciences, Inc. (AURA) Stock Analysis: Unpacking a 259% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Aug Big Picture: Can Aura Biosciences Inc benefit from deglobalizationQuarterly Earnings Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (AURA) Movement - Stock Traders Daily
Should you buy the dip on Aura Biosciences Inc.2025 Valuation Update & Weekly High Conviction Ideas - mfd.ru
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aura Biosciences, Inc. (AURA) Stock Analysis: A Biotech Player with a Potential Upside of 237% - DirectorsTalk Interviews
AURA Should I Buy - Intellectia AI
Discipline and Rules-Based Execution in AURA Response - Stock Traders Daily
Guidance Update: Can Aura Biosciences Inc deliver alphaTrade Entry Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Aura Biosciences, Inc. (AURA): Investor Outlook with a Remarkable 257.93% Potential Upside - DirectorsTalk Interviews
Following a 29% decline over last year, recent gains may please Aura Biosciences, Inc. (NASDAQ:AURA) institutional owners - simplywall.st
WhiteFiber Inc (WYFI) Announces $200 Million Convertible Notes Offering, Shares Drop 5.5% - intellectia.ai
WhiteFiber, T1 Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
We're Keeping An Eye On Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate - Yahoo Finance
Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket - Benzinga
Los Pinos Elisabet De Sells 16,928 Shares of Aura Biosciences (NASDAQ:AURA) Stock - Defense World
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock By Investing.com - Investing.com Australia
Behavioral Patterns of AURA and Institutional Flows - Stock Traders Daily
Top Executive Makes a Big Move With Aura Biosciences Stock - TipRanks
Aura Biosciences CEO de los Pinos sells $82k in stock - Investing.com Canada
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock - Investing.com
Big Picture: How does Aura Biosciences Inc perform in inflationary periodsMarket Risk Analysis & Safe Entry Point Alerts - baoquankhu1.vn
Is Postal Realty Trust Inc. in a long term uptrendWeekly Profit Summary & Daily Growth Stock Tips - bollywoodhelpline.com
RSI Check: Why hedge funds are buying Aura Biosciences Inc stockPortfolio Return Summary & Verified Chart Pattern Signals - Bộ Nội Vụ
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):